Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

4articles mentioning drugs

7drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: zimberelimab ×

zimberelimab

This drug is selected. Its supporting articles are shown below.

zimberelimab4

Articles mentioning zimberelimab

4 articles · page 1 of 1

648 A pilot study to evaluate the combination of zimberelimab, domvanalimab and etrumadenant in patients with previously treated non-small cell lung cancer (NSCLC)

jitc · abstract · 2025-11-04 · 3 matching annotations

97.5%

etrumadenant zimberelimab domvanalimab NSCLC Washington University metastatic non-small cell lung cancer

…relimab 360mg IV q3 weeks, domvanalimab 15mg/kg IV q3 weeks and etrumadenant 150mg PO daily. The primary endpoint was objective response rat…

589 A first in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in participants with advanced solid malignancies

jitc · abstract · 2025-11-04 · 2 matching annotations

93.1%

COM503 zimberelimab GS-0321

…primary objectives are to assess the safety and tolerability of COM503 as monotherapy and in combination with zimberelimab and identif…

170 Peripheral pharmacodynamic analysis of anti-CD39 monoclonal antibody AB598 in a first-in-human phase I trial in patients with advanced solid tumors

jitc · abstract · 2025-11-04 · 1 matching annotations

94.2%

AB598 AB598-mediated AB598-dosed zimberelimab mFOLFOX advanced solid tumors GEJ cancer NCT05891171

…tics (PK), pharmacodynamics (PD), and clinical activity of both AB598 monotherapy and AB598 in combination with zimberelimab (anti-PD…

184 Tumor biomarker analysis of anti-CD39 monoclonal antibody AB598 in a first-in-human phase I trial in patients with advanced solid tumors

jitc · abstract · 2025-11-04 · 1 matching annotations

96.1%

AB598 zimberelimab ARC-25 solid tumors advanced solid tumors

…immunological modulation, are positively correlated.Conclusions AB598 achieved complete CD39 target engagement and inhibition across …